Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Clinical and Prognostic Significance of the Epithelial-Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Score-Matched Analysis.

Matsubara T, Tagawa T, Takada K, Toyokawa G, Shimokawa M, Kozuma Y, Akamine T, Haro A, Osoegawa A, Mori M.

Clin Lung Cancer. 2019 Apr 19. pii: S1525-7304(19)30086-5. doi: 10.1016/j.cllc.2019.04.006. [Epub ahead of print]

PMID:
31103348
2.

Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas.

Kinoshita F, Toyokawa G, Matsubara T, Kozuma Y, Haratake N, Takamori S, Akamine T, Hirai F, Takenaka T, Tagawa T, Maehara Y.

Anticancer Res. 2019 May;39(5):2665-2670. doi: 10.21873/anticanres.13391.

PMID:
31092466
3.

The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.

Matsubara T, Toyokawa G, Takada K, Kinoshita F, Kozuma Y, Akamine T, Shimokawa M, Haro A, Osoegawa A, Tagawa T, Mori M.

PLoS One. 2019 May 1;14(5):e0215103. doi: 10.1371/journal.pone.0215103. eCollection 2019.

4.

First Case of a Primary Lung Granulosa Cell Tumor With a Mutation in the Forkhead Box L2 Gene.

Izuwa A, Toyokawa G, Shoji F, Yamazaki K, Momosaki S, Furuya K, Yamada Y, Oda Y, Takeo S.

J Thorac Oncol. 2019 May;14(5):e100-e102. doi: 10.1016/j.jtho.2018.12.029. No abstract available.

PMID:
31027742
5.

A novel prognostic marker in patients with non-small cell lung cancer: musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase.

Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Tagawa T, Oda Y, Maehara Y.

J Thorac Dis. 2019 Mar;11(3):927-935. doi: 10.21037/jtd.2019.01.76.

6.

Significance of the Red Blood Cell Distribution Width in Resected Pathologic Stage I Nonsmall Cell Lung Cancer.

Toyokawa G, Shoji F, Yamazaki K, Shimokawa M, Takeo S.

Semin Thorac Cardiovasc Surg. 2019 Apr 19. pii: S1043-0679(19)30134-0. doi: 10.1053/j.semtcvs.2019.04.011. [Epub ahead of print]

PMID:
31009697
7.

Lorlatinib for the treatment of patients with non-small cell lung cancer.

Akamine T, Toyokawa G, Tagawa T, Yamazaki K, Seto T, Takeo S, Mori M.

Drugs Today (Barc). 2019 Feb;55(2):107-116. doi: 10.1358/dot.2019.55.2.2927983.

PMID:
30816885
8.

A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.

Matsubara T, Takada K, Azuma K, Takamori S, Toyokawa G, Haro A, Osoegawa A, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1925-1933. doi: 10.1245/s10434-019-07257-3. Epub 2019 Feb 27.

PMID:
30815803
9.

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.

Takamori S, Takada K, Azuma K, Jogo T, Shimokawa M, Toyokawa G, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1916-1924. doi: 10.1245/s10434-019-07231-z. Epub 2019 Feb 27.

PMID:
30815801
10.

The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation.

Akamine T, Tagawa T, Ijichi K, Toyokawa G, Takamori S, Hirai F, Okamoto T, Oda Y, Maehara Y.

Ann Surg Oncol. 2019 May;26(5):1544-1551. doi: 10.1245/s10434-018-07137-2. Epub 2019 Feb 24.

PMID:
30798450
11.

The prognostic impact of obstructive lung disease on survival of never smokers with resected non-small-cell lung cancer: a comparison with smokers.

Akamine T, Tagawa T, Shimokawa M, Matsubara T, Kozuma Y, Haratake N, Takamori S, Toyokawa G, Maehara Y.

Interact Cardiovasc Thorac Surg. 2019 Jan 2. doi: 10.1093/icvts/ivy329. [Epub ahead of print]

PMID:
30602039
12.

ALK testing methods: is there a winner or loser?

Kozuma Y, Toyokawa G, Seto T.

Expert Rev Anticancer Ther. 2019 Mar;19(3):237-244. doi: 10.1080/14737140.2019.1562343. Epub 2018 Dec 28.

PMID:
30576255
13.

HMGB1 blockade significantly improves luminal fibrous obliteration in a murine model of bronchiolitis obliterans syndrome.

Takamori S, Shoji F, Okamoto T, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Takada K, Toyokawa G, Tagawa T, Maehara Y.

Transpl Immunol. 2019 Apr;53:13-20. doi: 10.1016/j.trim.2018.11.007. Epub 2018 Dec 1.

PMID:
30508580
14.

Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.

Takamori S, Takada K, Tagawa T, Toyokawa G, Hirai F, Yamashita N, Okamoto T, Oki E, Yoshizumi T, Oda Y, Maehara Y.

Surg Oncol. 2018 Dec;27(4):637-641. doi: 10.1016/j.suronc.2018.08.001. Epub 2018 Aug 11.

PMID:
30449485
15.

Atezolizumab in non-squamous non-small cell lung cancer.

Akamine T, Toyokawa G, Tagawa T, Seto T.

J Thorac Dis. 2018 Sep;10(Suppl 26):S3155-S3159. doi: 10.21037/jtd.2018.07.92. No abstract available.

16.

Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.

Takada K, Toyokawa G, Azuma K, Takamori S, Jogo T, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

In Vivo. 2018 Nov-Dec;32(6):1541-1550. doi: 10.21873/invivo.11412.

17.

A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.

Toyokawa G, Takada K, Tagawa T, Hamamoto R, Yamada Y, Shimokawa M, Oda Y, Maehara Y.

Ann Thorac Surg. 2019 Feb;107(2):393-400. doi: 10.1016/j.athoracsur.2018.08.056. Epub 2018 Oct 18.

PMID:
30343006
18.

Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.

Takamori S, Takada K, Azuma K, Jogo Y, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Toyokawa G, Hirai F, Tagawa T, Okamoto I, Nakanishi Y, Kawahara A, Akiba J, Oda Y, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5903-5907. doi: 10.21873/anticanres.12934.

PMID:
30275217
19.

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.

Takamori S, Takada K, Toyokawa G, Azuma K, Shimokawa M, Jogo T, Yamada Y, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5897-5901. doi: 10.21873/anticanres.12933.

PMID:
30275216
20.

A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.

Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tsukamoto S, Hamatake M, Yokoyama H, Ueda H, Motohiro A, Tagawa T, Shoji F, Kometani T, Saito G, Fukuyama Y, Toyokawa G, Osoegawa A, Emi Y, Maehara Y; Kyushu University Lung Surgery Study Group (KLSS) Japan.

Lung Cancer. 2018 Oct;124:255-259. doi: 10.1016/j.lungcan.2018.08.015. Epub 2018 Aug 19.

PMID:
30268470
21.

Sarcopenia After Resection of Early Non-small Cell Lung Cancer: Is Postoperative Skeletal Muscle Loss a Risk Factor for Poor Outcomes?

Takamori S, Toyokawa G.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):946-947. doi: 10.1245/s10434-018-6784-z. Epub 2018 Sep 22. No abstract available.

PMID:
30244420
22.

Radiological Features of IDO1+/PDL1+ Lung Adenocarcinoma: A Retrospective Single-institution Study.

Takada K, Toyokawa G, Tagawa T, Shimokawa M, Kohashi K, Haro A, Osoegawa A, Oda Y, Maehara Y.

Anticancer Res. 2018 Sep;38(9):5295-5303. doi: 10.21873/anticanres.12856.

PMID:
30194181
23.

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date.

Akamine T, Toyokawa G, Tagawa T, Seto T.

Onco Targets Ther. 2018 Aug 22;11:5093-5101. doi: 10.2147/OTT.S165511. eCollection 2018. Review.

24.

Significance of spread through air spaces in early-stage lung adenocarcinomas undergoing limited resection.

Toyokawa G, Yamada Y, Tagawa T, Oda Y.

Thorac Cancer. 2018 Oct;9(10):1255-1261. doi: 10.1111/1759-7714.12828. Epub 2018 Aug 6.

25.

Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.

Kozuma Y, Takada K, Toyokawa G, Kohashi K, Shimokawa M, Hirai F, Tagawa T, Okamoto T, Oda Y, Maehara Y.

Eur J Cancer. 2018 Sep;101:20-29. doi: 10.1016/j.ejca.2018.06.020. Epub 2018 Jul 13.

PMID:
30014971
26.

Computed tomography features of resected lung adenocarcinomas with spread through air spaces.

Toyokawa G, Yamada Y, Tagawa T, Kamitani T, Yamasaki Y, Shimokawa M, Oda Y, Maehara Y.

J Thorac Cardiovasc Surg. 2018 Oct;156(4):1670-1676.e4. doi: 10.1016/j.jtcvs.2018.04.126. Epub 2018 Jun 6.

PMID:
29961590
27.

Stevens-Johnson Syndrome Induced by Pembrolizumab in a Lung Cancer Patient.

Haratake N, Tagawa T, Hirai F, Toyokawa G, Miyazaki R, Maehara Y.

J Thorac Oncol. 2018 Nov;13(11):1798-1799. doi: 10.1016/j.jtho.2018.05.031. Epub 2018 Jun 6. No abstract available.

PMID:
29885481
28.

Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring EGFR Mutation.

Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N, Hirai F, Tagawa T, Oda Y, Iwaki T, Iihara K, Honda H, Maehara Y.

Anticancer Res. 2018 Jun;38(6):3731-3734. doi: 10.21873/anticanres.12653.

PMID:
29848735
29.

Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.

Toyokawa G, Takada K, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Yamada Y, Hamamoto R, Oda Y, Maehara Y.

Anticancer Res. 2018 Jun;38(6):3707-3711. doi: 10.21873/anticanres.12649.

PMID:
29848731
30.

The significant influence of having children on the postoperative prognosis of patients with nonsmall cell lung cancer: A propensity score-matched analysis.

Takamori S, Tagawa T, Toyokawa G, Ueo H, Shimokawa M, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Akamine T, Katsura M, Takada K, Hirai F, Shoji F, Okamoto T, Oda Y, Maehara Y.

Cancer Med. 2018 May 29. doi: 10.1002/cam4.1539. [Epub ahead of print]

31.

Significance of Spread Through Air Spaces in Resected Lung Adenocarcinomas With Lymph Node Metastasis.

Toyokawa G, Yamada Y, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Oda Y, Maehara Y.

Clin Lung Cancer. 2018 Sep;19(5):395-400.e1. doi: 10.1016/j.cllc.2018.04.002. Epub 2018 Apr 18.

PMID:
29735272
32.

Successful Treatment of Growing Teratoma Syndrome of the Lung by Surgical Resection: A Case Report and Literature Review.

Tanaka K, Toyokawa G, Tagawa T, Ijichi K, Haratake N, Hirai F, Oda Y, Maehara Y.

Anticancer Res. 2018 May;38(5):3115-3118. Review.

PMID:
29715149
33.

Takotsubo Cardiomyopathy Developed After Two-stage Surgery for Double Primary Lung Cancer.

Kinoshita F, Toyokawa G, Tagawa T, Matsubara T, Kozuma Y, Haratake N, Takamori S, Akamine T, Hirai F, Maehara Y.

Anticancer Res. 2018 May;38(5):2957-2960.

PMID:
29715123
34.

Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.

Akamine T, Takada K, Toyokawa G, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa T, Okamoto T, Yoneshima Y, Okamoto I, Shimokawa M, Oda Y, Nakanishi Y, Maehara Y.

Surg Oncol. 2018 Mar;27(1):88-94. doi: 10.1016/j.suronc.2018.01.002. Epub 2018 Jan 9.

PMID:
29549910
35.

Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung.

Okamoto T, Takada K, Sato S, Toyokawa G, Tagawa T, Shoji F, Nakanishi R, Oki E, Koike T, Nagahashi M, Ichikawa H, Shimada Y, Watanabe S, Kikuchi T, Akazawa K, Lyle S, Takabe K, Okuda S, Sugio K, Wakai T, Tsuchida M, Maehara Y.

Ann Surg Oncol. 2018 Jun;25(6):1564-1571. doi: 10.1245/s10434-018-6401-1. Epub 2018 Mar 2.

PMID:
29500766
36.

The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.

Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Seto T, Tagawa T, Takenoyama M, Ichinose Y, Maehara Y.

Ann Surg Oncol. 2018 Jun;25(6):1555-1563. doi: 10.1245/s10434-018-6385-x. Epub 2018 Mar 2.

PMID:
29500763
37.

High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer.

Toyokawa G, Yamada Y, Tagawa T, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Hirai F, Oda Y, Maehara Y.

Anticancer Res. 2018 Mar;38(3):1821-1825.

PMID:
29491122
38.

Safety of Simultaneous Bilateral Pulmonary Resection for Metastatic Lung Tumors.

Matsubara T, Toyokawa G, Kinoshita F, Haratake N, Kozuma Y, Akamine T, Takamori S, Hirai F, Tagawa T, Okamoto T, Maehara Y.

Anticancer Res. 2018 Mar;38(3):1715-1719.

PMID:
29491107
39.

Significance of Spread Through Air Spaces in Resected Pathological Stage I Lung Adenocarcinoma.

Toyokawa G, Yamada Y, Tagawa T, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Oda Y, Maehara Y.

Ann Thorac Surg. 2018 Jun;105(6):1655-1663. doi: 10.1016/j.athoracsur.2018.01.037. Epub 2018 Feb 14.

PMID:
29453963
40.

PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.

Takada K, Toyokawa G, Tagawa T, Kohashi K, Shimokawa M, Akamine T, Takamori S, Hirai F, Shoji F, Okamoto T, Oda Y, Maehara Y.

Lung Cancer. 2018 Feb;116:1-6. doi: 10.1016/j.lungcan.2017.12.003. Epub 2017 Dec 7.

PMID:
29413045
41.

Which Primary Organ Is Most Suitable for Performing Pulmonary Metastasectomy?

Hirai F, Kinoshita I, Matsubara T, Haratake N, Kouzuma Y, Takamori S, Akamine T, Toyokawa G, Tagawa T, Takenoyama M, Maehara Y.

Anticancer Res. 2018 Feb;38(2):1041-1045.

PMID:
29374738
42.

Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer.

Takamori S, Toyokawa G, Okamoto T, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takada K, Katsura M, Hirai F, Shoji F, Tagawa T, Oda Y, Honda H, Maehara Y.

Ann Surg Oncol. 2018 May;25(5):1229-1236. doi: 10.1245/s10434-017-6328-y. Epub 2018 Jan 11.

PMID:
29327178
43.

Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.

Takamori S, Toyokawa G, Okamoto I, Takada K, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N, Hirai F, Tagawa T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y.

Anticancer Res. 2018 Jan;38(1):553-557.

PMID:
29277823
44.

Programmed Death-Ligand 1 Expression and EGFR Mutations in Multifocal Lung Cancer.

Haratake N, Toyokawa G, Takada K, Kozuma Y, Matsubara T, Takamori S, Akamine T, Katsura M, Shoji F, Okamoto T, Oda Y, Maehara Y.

Ann Thorac Surg. 2018 Feb;105(2):448-454. doi: 10.1016/j.athoracsur.2017.09.025. Epub 2017 Dec 15.

PMID:
29254651
45.

Highlighted version successful resection of a tracheal metastasis of rectal cancer: a case report.

Akamine T, Toyokawa G, Kohashi K, Matsubara T, Kozuma Y, Haratake N, Takamori S, Katsura M, Takada K, Shoji F, Okamoto T, Oda Y, Maehara Y.

J Thorac Dis. 2017 Sep;9(9):E797-E800. doi: 10.21037/jtd.2017.07.94. Erratum in: J Thorac Dis. 2017 Oct;9(10 ):E978.

46.

Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma.

Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T, Takada K, Katsura M, Shimokawa M, Shoji F, Okamoto T, Maehara Y.

J Thorac Dis. 2017 Sep;9(9):2942-2951. doi: 10.21037/jtd.2017.07.108.

47.

Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer.

Takada K, Toyokawa G, Tagawa T, Kohashi K, Akamine T, Takamori S, Hirai F, Shoji F, Okamoto T, Oda Y, Maehara Y.

Anticancer Res. 2017 Dec;37(12):7073-7082.

PMID:
29187498
48.

Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer.

Shoji F, Matsubara T, Kozuma Y, Haratake N, Akamine T, Takamori S, Katsura M, Toyokawa G, Okamoto T, Maehara Y.

Anticancer Res. 2017 Dec;37(12):6997-7003.

PMID:
29187486
49.

A Case of the Resected Lymphohistiocytoid Mesothelioma: BAP1 Is a Key of Accurate Diagnosis.

Matsubara T, Toyokawa G, Yamada Y, Nabeshima K, Haratake N, Kozuma Y, Akamine T, Takamori S, Shoji F, Okamoto T, Maehara Y.

Anticancer Res. 2017 Dec;37(12):6937-6941.

PMID:
29187476
50.

The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.

Takada K, Toyokawa G, Shoji F, Okamoto T, Maehara Y.

Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28. Review.

PMID:
29153898

Supplemental Content

Loading ...
Support Center